Gilead Sciences News

Gilead Sciences is a multi-billion dollar biopharmaceutical company that develops medicines for a range of diseases. It is research based, so to stay up-to-date with that research, and to keep track of the performance of the company along with other issues, sign up for the Wiser Gilead Sciences news email. The drugs that Gilead Services produces treat conditions like HIV/AIDS, liver disease, cancer, cardiovascular and respiratory conditions. The company was founded in 1987 and is based in California. The president and chief executive officer is John Martin. It has about 7,000 employees and is ranked as one of the top drug companies in the US with sales in 2013 of over $11 billion. Its hepatitis-C drug, Sovaldi, is predicted to sell well, plus it is expected to continue its expansion through acquisitions. This is in addition to new drugs that the company is developing. The Gilead Sciences news email from Wiser is the best way to get the latest news and information on the company. It is free, so register today.

Recent Gilead Sciences News Coverage
 
Your Weekly Recommendations Saturday, February 25, 2017
 
Recommended for you
Better Buy: Eli Lilly and Co vs. GlaxoSmithKline plc
Fool.com: The Motley Fool • Cory Renauer
Pfizer Subpoenaed in DOJ Investigation of Drugmaker Charity Connections
Bloomberg • Robert Langreth
What I'm Doing With My Gilead Sciences Shares
Seeking Alpha • Canadian Dividend Growth Investor
Cures on loan
Week in Review • Erin Mccallister
Refining moment
Week in Review • Erin Mccallister
Invest, not ingest
Week in Review • B.C. Staff
That was then; this is now
Week in Review • B.C. Staff
Gilead's arithmetic problem
Week in Review • B.C. Staff
Combo deals
Week in Review • Stephen Hansen
I'm Sick And Tired Of Gilead Sciences: Part 2
Seeking Alpha • Nicholas Ward
 
Recommended for You
Gilead Sciences, GlaxoSmithKline plc
Better Buy: Eli Lilly and Co vs. GlaxoSmithKline plc
Fool.com: The Motley FoolCory Renauer
A couple recent events helped shares of Eli Lilly and Co (NYSE:LLY) bounce back from a big clinical trial failure that sent the stock tumbling late last year. Despite some ups and downs over the past year, the big pharma stock notched...
Share
Gilead Sciences, Medicare
Pfizer Subpoenaed in DOJ Investigation of Drugmaker Charity Connections
BloombergRobert Langreth
Pfizer Inc. said that it received two subpoenas from the U.S. Attorney’s office in Massachusetts related to charities that help Medicare patients afford co-payments for drugs, the latest company to disclose involvement in the probe. The New York-based drugmaker said in a...
Share
Gilead Sciences, Health Finance
What I'm Doing With My Gilead Sciences Shares
Seeking AlphaCanadian Dividend Growth Investor
Summary Gilead shares have declined 40% since July 2015. I noticed some investors have sold the stock and moved on. I wondered if I should do the same. I've decided to hold on for now. Here's why. It's never a pretty sight...
Share
Credit Cards, Credit Services
Cures on loan
Week in ReviewErin Mccallister
Massachusetts Institute of Technology and Dana-Farber Cancer Institute researchers have proposed a model that seeks to alleviate the upfront cost of expensive new therapies for payers and patients. But unless companies share the risk, the idea might not have traction with the...
Share
Credit Cards, Credit Services
Refining moment
Week in ReviewErin Mccallister
As CMS contemplates an experiment with value-based payment models, private payers and PBMs are already finding that such methods can decrease their reliance on some of the blunt instruments they've used to beat down drug costs. Experiments with new reimbursement tools were...
Share
Business Ethics, Gilead Sciences
Invest, not ingest
Week in ReviewB.C. Staff
There are myriad reasons for pharma and big biotech to make investments in fledgling companies through corporate venture arms, but data suggest M&A is not one of them. The latest example is Nimbus Therapeutics LLC, which last week sold its Nimbus Apollo...
Share
Gilead Sciences
That was then; this is now
Week in ReviewB.C. Staff
It's impossible to define how much of last week's jump in Biogen Inc. (NASDAQ:BIIB) shares related to CEO George Scangos' pending departure announced Thursday, and how much reflected the strong 2Q16 earnings reported the same day. But after 15 months of clinical...
Share
Gilead Sciences
Gilead's arithmetic problem
Week in ReviewB.C. Staff
Declining HCV sales and lower guidance from Gilead Sciences Inc. (NASDAQ:GILD) shaved about $10 billion off the bellwether's market cap last Tuesday and renewed investor calls for the company to do a splashy deal to vault its growth back in line with...
Share
Gilead Sciences
Combo deals
Week in ReviewStephen Hansen
Allergan plc's two NASH acquisitions give it the second biggest pipeline for the indication and enough mechanisms to develop in-house combinations that could target multiple drivers of the disease pathophysiology. Together, Allergan's Sept. 20 deals to acquire Tobira Therapeutics Inc. and Akarna...
Share
Gilead Sciences, GlaxoSmithKline plc
I'm Sick And Tired Of Gilead Sciences: Part 2
Seeking AlphaNicholas Ward
Summary After liquidating my GILD position in December at $74.39 for tax loss purposes, I recently bought back GILD shares at $67.48. After the February sell-off and the recent dividend increase, GILD's dividend yield rose above the 3% threshold. This remains a...
Share